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INTRODUCTION: Cervical cancer is the second commonest cancer in South Africa 
and the commonest amongst Black females with a Lifetime Risk (LR) of 1:35. In South 
Africa the problem has been compounded by the HIV epidemic as well as a lack of 
resources and infrastructure to offer an adequate screening and treatment programme. 
Cone biopsies are one of the diagnostic and sometimes therapeutic modalities used to 
assess and treat cervical precursors and cervical cancer. Unfortunately, cone biopsy of the 
cervix remains a morbid procedure often performed on young women in the reproductive 
age group and has resultant complications.   
 
OBJECTIVE:  To audit the demographics, indications, histology and post cone 
management and outcome of women requiring cone biopsies of the cervix, at Groote 
Schuur Hospital Colposcopy Clinic between 1st April 2010 and 31st October 2013. 
 
METHODS: A group of women attending the colposcopy clinic, and requiring cone 
biopsies between 1st April 2010 and 31st October 2013 were identified from a 
computerized database, known as the Hygiena Database.  Women who had an incomplete 
dataset were excluded. Folder review and review of the National Health Laboratory 
Services was also conducted. Patient demographics, indications, cone histology and 
follow up at 4-6 months, 10-12 months and > 12 months were analysed. Age, parity, HIV 
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status, CD4 count, ARV status and cone margin involvement were included in the 
univariate and multivariate analysis to determine predictors of persistent disease 
RESULTS: Three hundred and seventy six cone biopsies were performed during the 
study period, with a mean age of 42.3 years, mean parity of 2. The majority of women  
[56,7% (213/376)] were HIV positive. The final histology indicated that 65,2% (246/376) 
of the women had high-grade disease (CIN 2/3 or HSIL) and 12,5% (47/376) had 
microinvasion. Ectocervical margins were clear in 57,6% (212/368) of cases and 
endocervical margins were clear in 54,6% (201/368) of specimens. Fifty-one cancers 
were detected during the study period. In the multivariate analysis age 40-49yrs (RR 1.4, 
95% CI 1.01-2.0: p=0,043), ectocervical margin involvement with CIN 2/3 (RR 1.8, 95% 
CI 1.1-3.0: p-0.017) and endocervical margin involvement with CIN 2/3 (RR 1.5, 95% CI 
1.04-2.3; p=0,031) and microinvasion ( RR 2.4, 95% CI 1.4-4.3; p=0.003) were all 
predictors of persistent disease.  
CONCLUSION: The use of cone biopsy is a valid diagnostic and sometimes therapeutic 
procedure at Groote Schuur Hospital with significant detection of high grade disease and 
cervical cancer. Women aged 40-49 years and positive cone margins are strong predictors 
of persistent disease. Improved compliance and a reduction in positive margins are two 
areas that need to be addressed to improve the current treatment  programme. Use of cone 
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CHAPTER 1 : INTRODUCTION AND LITERATURE REVIEW 
 
 
Magnitude of the Problem 
 
 
Cervical cancer is the 4th commonest cancer in women globally, after breast, lung and 
colorectal cancer, and the seventh most common overall. More than 85% of the global 
burden occurs in developing countries where it accounts for 12% of all female cancers 
(Globocan 2012). 
According to worldwide estimates of cancer compiled by the International Agency for 
Research on Cancer  (IARC), 528 000 new cases of cervical cancer were diagnosed 
globally in 2012. High-risk regions, with estimated age standardized rates (ASRs) over 
30 per 100,000, include Eastern Africa (42.7), Melanesia (33.3), Southern (31.5) and 
Middle (30.6) Africa. Rates are lowest in Australia/New Zealand (5.5) and Western Asia 
(4.4). Cervical cancer remains the most common cancer in women in Eastern and Middle 
Africa (Globocan 2012). 
 
There is a significant discrepancy in the incidence of and mortality from cervical cancer 
in different regions of the world.  There were an estimated 266,000 deaths from cervical 
cancer worldwide in 2012, accounting for 7.5% of all female cancer deaths. Almost nine 
out of ten (87%) cervical cancer deaths occurred in less developed regions. Mortality 
varied 18-fold between the different regions of the world, with rates ranging from less 
than 2 per 100,000 in Western Asia, Western Europe and Australia/New Zealand to more 
than 20 per 100,000 in Melanesia (20.6), Middle (22.2) and Eastern (27.6) Africa 
(Globocan 2012)  
 12 
 
                                          Estimated age-standardised rates (World) per 100,000 
FIGURE 1.1 : Estimated Cervical Cancer Incidence and Mortality Worldwide in 2012  
(International Agency for Research on Cancer, World Health Organization, 
2012, GLOBOCAN 2012. Available from: <http://globocan.iarc.fr/.) 
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Cervical cancer in low resource settings 
The marked disparity in cervical cancer incidence in low-versus high resource regions 
highlights the absence of effective national cervical cancer screening programmes in 
most low resource countries. A comprehensive analysis of data by the IARC in 1986 
showed that well organised screening programmes were effective in reducing the 
incidence of and mortality from cervical cancer (IARC Working Group, 1986). In 
Scandinavian countries, national screening programmes implemented since the 1960’s 
have significantly reduced cervical cancer incidence and mortality (Laara et al 1987; 
Hakama & Louhivuori 1988). The greatest fall in mortality was in Iceland (84% from 
1965 to 1982) where the screening  interval was the shortest and the target age range was 
the widest. 
 
In the South African National Cancer Registry (pathologically based) in 2007, cervical 
cancer was the second most common cancer in women after breast cancer. It accounted 
for 18,1 % of all cancers in women, with ASIR of 21.78/100 000 and a lifetime risk (LR) 
of 1:42 for all South African women. The LR increased to 1:35 for Black South African 
women making it the most common cancer in this group, and accounting for 30% of 
cancers in black females. These statistics should be seen in the context of cervical cancer 
as a preventable and curable disease (National Cancer Registry Report 2007). 
 
In Sub-Saharan Africa and South Africa in particular, the problem has been compounded 
by the HIV/Aids epidemic, where 70% of the world’s cases are diagnosed 
[www.unaids.org].  According to Stats SA, the total number of persons living with HIV 
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in South Africa increased from an estimated 4 million in 2002 to 5,26 million by 2013. In 
2013 an estimated 10% of the total population was calculated to be HIV positive 
(Statistics South Africa 2013). The prevalence of HIV among South African women 
attending antenatal clinics in 2011 was 29,5% (South African National Department of 
Health 2011). It is well documented that HIV infection increases the risk of developing 
certain cancers, namely Kaposi’s sarcoma, Non-Hodgkin’s lymphoma and cervical 
cancer, all of which were classified as AIDS- defining diseases by the Centre for Disease 
Control (CDC) in 1993(MMWR Recommendation Report 1992). According to Denny et 
al (2008), a strong relationship exists between HIV and HPV.  The natural history of 
cervical neoplasia is one of progression and regression, partially mediated by local 
cervical immunity and a complex interaction with a range of co-factors (Stanley 2006). In 
HIV-positive women with cervical intraepithelial neoplasia (CIN), both pro-
inflammatory and anti-inflammatory pathways in the cervical mucosa were found to be 
suppressed, in comparison with the local mucosal environment of HIV-negative women 
(Kobayashi, Greenblatt & Anastos et al 2004).  
 
Natural History of Cervical Cancer  
The evolution of cervical cancer has been well studied in the last half of the 20th century. 
A wealth of evidence now exists that implicates persistent infection with high risk 
/oncogenic types of HPV as the main cause of cervical cancer (Walboomers et al 1999). 
High risk HPV types are identified in nearly all types of carcinomas of the cervix and the 
relative risk of cervical cancer associated with high risk HPV types is higher than the risk 
of lung cancer associated with smoking (Munoz et al 2003). 
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The human papillomavirus is a tightly coiled, circular, double stranded DNA with 8000 
base pairs in their genome. It is an obligatory intranuclear virus that must infect 
mitotically active cells to institute infection. HPV infection of the cervix affects the 
developing immature metaplastic cells of the transformation zone at the squamo-
columnar junction, which explains why HPV is associated with both squamous and 
glandular neoplasia. Over 150 different HPV types have been identified, of which 
approximately 30-40% infect the anogenital tract. They are commonly classified into 15 
oncogenic ( HPV 16,18,31,35,39,45,51,52,56,58,59,68,73,82) and 12 non-oncogenic 
types (HPV 6,11,40,42,43,44, 54,61,70,72,81 and CP6108) (Munoz et al 2003). Pre 
malignant and malignant cells arise as result of DNA integration into the host cellular 
genome, and over expression of the viral E6 and E7 oncogenes. Cells acquire a 
proliferative advantage by escaping growth control exerted by p53 and pRb. Both cellular 
proteins are inactivated respectively by E6 and E7 proteins. Aneuploidy and karyotypic 
abnormalities are also key events in the tumour progression. 
HPV is transmitted through sexual contact, and transmission occurs through mechanical 
abrasion of an infected epithelial surface with an uninfected epithelium.  HPV’s that are 
primarily transmitted through sexual contact, are found in 99% of cases of invasive 
cervical cancer. The incidence of HPV is highest amongst young women, and although 
most men and women can be infected during their sexual life, most are asymptomatic 
with transient infection. A small minority, with persistent infection will progress to 
dysplasia and subsequently to cancer (Cox 2006). 
 The vast majority of HPV viral infections are cleared within 8-18 months in women with 
competent immune systems. However, through a complicated cascade of events some 
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infections evade the immune system, becoming a persistent infection, which is necessary 
for the development of and progression of precancerous lesions of the cervix, either to 
high grades of precancerous disease or to cancer (Wright, Kurman & Ferenczy 2002). 
Cervical cancer precursors are now classified into low grade squamous intraepithelial 
lesions (LSIL)(previously cervical intraepithelial neoplasia 1) or high grade squamous 
intraepithelial lesions (HSIL) (CIN 2 and 3). 
 
HPV and Cervical Precursor Lesions in HIV Infected Women 
As previously mentioned, a strong relationship exists between HPV and HIV. HIV is 
thought to increase the risk of HPV replication or transcription by a direct viral-viral 
interaction (Dolei, Curreli & Marongei  1999; Vernon, Haart, Reeves & Icenogle 1993). 
  
Studies have consistently shown higher prevalence of HPV infection, persistent infection 
with HPV, infection with multiple types of HPV and higher prevalence of cervical cancer 
precursors in HIV infected women and presentation at an earlier age with cervical cancer 
(Singh et al 2009; Ellerbrock et al 2000; Harris et al 2005).   
In 2005, a prospective observational study of 710 HIV positive and 226 HIV negative 
women, was undertaken in Rwanda. The prevalence of HPV was higher in HIV positive 
women compared to HIV negative women, with a peak of 75% in the 25 – 34 year age 
group and then declined with increasing age to 37.5% in those over 55years ( p<0,001). 
Among the HIV positive women, 35% were infected with multiple types of HPV and 
46% with carcinogenic HPV types. A significant trend of higher prevalence of HPV and 
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carcinogenic HPV with lower CD4+cell counts and increasing cytologic severity was 
also noted amongst HIV positive women (Singh et al 2009). 
These findings were further supported by a recent study by McDonald et al (2014) in 
Cape Town, South Africa where 1 371 HIV positive women and 8 050 HIV negative 
women with no history of cervical screening were recruited from the general population. 
All the women were tested for HIV, cervical samples were tested for high risk HPV DNA 
and CIN status was based on colposcopy and biopsy. They found a higher prevalence of 
HPV amongst HIV positive compared to HIV negative women (52,4% vs. 20,8%) overall 
and in all age groups. High grade lesions, infection with high risk HPV types and 
multiple HPV types was more common among HIV positive than HIV negative women.  
 
HIV positive women have higher rates of HPV and cervical abnormalities than HIV 
negative women. The natural history of HPV infection and cervical disease in HIV-1 
infected women was studied  by Denny et al (2008) who found that 68% of their cohort 
of HIV positive women were infected with high risk types of HPV with 94% of these 
infections persisting over a 36 month period and only 6 % clearing their infections. 
Overall, 35% of women had a LSIL lesion on Pap smear and 13% HSIL on entry. 
The vast majority of LSILs regress spontaneously in immunocompetent women, however 
HIV positive women with LSIL have a lower rate of regression and more tendency to 
progression. Massad et al (2001) noted progression of cervical dysplasia in 14% of HIV 
infected women compared to 7% of HIV negative women, with regression to normal 
being lower in HIV positive women ( 43% vs. 66%.). HIV status, HPV detection of high 
risk types,  CD4 count and viral load predicted the incidence of cytologic abnormalities. 
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Several studies have shown that invasive cervical cancer in HIV positive women tends to 
present 10-15years earlier than their seronegative counterparts, and those with CD4 
counts <200 present with more advanced stage disease (Lomalisa, Smith & Guidozzi 
2000 ; Moodley, Moodley & Kleinschmidt 2001). 
 
As demonstrated above women infected with HIV, have an increased risk of being 
infected with HPV, multiple strains of oncogenic HPV, high grade lesions and therefore 
cervical cancer. However, the expected increase in cervical diagnosis in Africa during the 
HIV pandemic has not been convincingly observed. This is most likely due to women 
dying of opportunistic infections prior to developing cervical cancer. However, in the era 
of anti-retrovirals where women are expected to live longer, the risk of high grade 
cervical lesions and cervical cancer remains high.  
 
  Cervical cancer progresses slowly over decades, from preinvasive cervical 
intraepithelial neoplasia (CIN) to invasive cervical cancer- a process that can take 10-30 
years. The long natural history of the disease offers a unique opportunity for screening 
and prevention prior to the development of invasive cancer. In addition the long latency 
period between primary infection and cancer emergence suggests that additional factors 
are involved in the process such as, among others, sexual behavior, immune status, 




Cervical Cancer prevention and treatment 
 
Cervical cancer prevention involves a two tiered approach. Primary prevention involving 
safe sexual practices and HPV vaccination and secondary prevention comprising 
cytology (pap smears), visual inspection of the cervix and HPV testing. 
 A vaccine against HPV has been one of the most exciting recent developments in 
cervical cancer prevention. The two vaccines currently available offer high levels of 
protection against persistent infection with oncogenic strains of HPV 16 and 18 
responsible for 70% of cervical cancers worldwide. These vaccines are prophylactic and 
require administration before the onset of sexual activity i.e. in prepubertal females. 
Studies by Goldie at al (2004), using modeling, and assuming 70% coverage of girls 9-
12yrs with vaccination against HPV 16 and 18, have shown a 43% reduction in lifetime 
risk of cervical cancer. 
 In addition HPV DNA testing has offered us another option in the arsenal of cervical 
cancer screening. Studies by Denny et al (2005 &2012) and Sanakaranarayanan et al 
(2007 & 2009), have shown that HPV DNA testing in combination with VIA (Visual 
inspection with acetic acid) or alone are effective in reducing high grade lesions,  and the 
incidence of cervical cancer and deaths particularly if screening is linked with treatment. 
Visual inspection with acetic acid (VIA) , involves examination of the cervix after 
application of 3-5% acetic acid, using the naked eye aided by a bright light source.  
 Unfortunately, in most low resource settings such as found in Africa, the above 
interventions have remained prohibitively expensive, and cervical cancer screening has 
relied on the detection of cervical cancer precursors using cervical cytology via the 
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Papanicolaou (pap) smear.  There are few, if any, successful cytology-based cervical 
cancer screening programmes in any developing countries, hence the large burden of 
disease. 
 
The South African National cervical screening programme offers 3 free Pap smears for 
asymptomatic women, beginning at age 30 and  each performed 10 years apart (South 
African National Department of Health 2003).  
   
Referral criteria for colposcopy include : 
- 3 consecutive smears with atypical squamous cell of undetermined significance 
(ASC-US) or 2 smears with low grade squamous intraepithelial lesion (LSIL) 
- 1 smear showing ASC – H (atypical squamous cells – HSIL cannot be excluded 
- high grade squamous intraepithelial lesion (HSIL)  
- Atypical Glandular lesions 
- macroscopically suspicious lesion of the cervix or Pap smear suspicious for 
microinvasion 
For women known with HIV, the clinical guidelines recommend a Pap smear at HIV 
diagnosis and with follow up every 3 years if normal, regardless of antiretroviral therapy 
(ART) status.  However, referral of HIV positive women for colposcopic evaluation is 
recommended after the first abnormal smear. 
 
At Groote Schuur Hospital, if a high grade precursor lesion is visualized at colposcopy, 
one of two approaches is used.  Either a biopsy is taken to confirm the diagnosis or an 
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immediate LLETZ is performed.  The criteria for LLETZ (considered a therapeutic 
procedure) include : 
• parity between cytology and colposcopic diagnosis 
• upper limit of lesion is seen 
• no evidence of glandular abnormality 
• no evidence of microinvasion 
By contrast, if the above criteria are not met a diagnostic cone biopsy is performed under 
the following circumstances : 
• marked disparity between cytology and colposcopy e.g. HSIL pap but negative 
colposcopy 
• upper limit of lesion not seen 
• evidence of glandular abnormality 
• evidence of microinvasion 
 
However, where a desire for future fertility exists, confirmatory biopsies are required 
before an excision procedure, which may be a LLETZ or Cone Biopsy. 
Cone biopsy of the cervix involves excision of the transformation zone and the 
endocervical canal as a cone shaped specimen, and is considered a diagnostic procedure, 
however it can be therapeutic.  It may be performed via loop diathermy (hot 
loop/electrodiathermy) or with a surgical scalpel (cold knife) and remains distinctly 
separate from LLETZ, which is a therapeutic procedure.  
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 Unfortunately, cone biopsy of the cervix remains a morbid procedure often performed on 
young women in the reproductive age group and has resultant complications.  Early 
complications include primary and secondary haemorrhage, sepsis and cervical stenosis 
and cervical incompetence. Late complications range from dysmenorrhoea, cervical 
stenosis resulting in infertility (sometimes requiring assisted reproductive techniques) and 
pregnancies associated with preterm prelabour rupture of membranes, preterm labour and 
low birth weight infants (Sozen et al 2014; Sadler et al 2004; Fanfani et al 2014). Sadler 
et al (2014) compared the delivery outcome of 426 untreated women with 652 treated 
women (via cone biopsy, laser ablation or LLETZ) at a colposcopy clinic in Auckland, 
New Zealand. The overall rate of preterm delivery was 13,8% and LLETZ and cone 
procedures were associated with a significantly increased risk of preterm rupture of 
membranes. This risk increased with increasing height of tissue removed from the cervix 
at conization. These findings were confirmed in a study by Sozen et al (2014) who found 
a significantly higher rate of preterm delivery and preterm prelabour rupture of 
membranes in the cohort of patients previously treated with cone biopsies. Cervical tissue 
volume rather than height of excised cervical tissue was found to be a more significant 
factor.  
 
Cone biopsies have also have an increasing role in oncology surgery for early stage 
cervical cancer. Particularly in the arena of fertility sparing surgery, it offers an 
alternative to hysterectomy for patients with stage early stage squamous carcinoma and 
adenocarcarcinoma in situ. Less radical surgery in the form of  cone biopsy (with 
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adequate margins) and sentinel nodes has offered another option to hysterectomy, thus 
alleviating the morbidity associated with more radical surgery ( Lee et al 2014). 
Bouchard Fortier, Reade & Covens (2014)  compared the outcomes of women with early 
stage cancer (stage 1Ai to 1Bi) treated with cone biopsy and pelvic lymphadenectomy 
versus simple hysterectomy and lymphadenectomy. Twenty two (43%) and twenty nine 
(57%) women underwent simple hysterectomy and cone biopsy respectively. The median 
tumour size was 10mm, median depth of invasion 2mm and lymphovascular space 
invasion (LVSI) was present in 35% of women. Surgical margins were all negative. Two 
women received adjuvant chemoradiaton for deep stromal invasion with LVSI and the 
other for pelvic metastases. Of the remainder, none had post- or intraoperative 
complications, the median blood loss was 100ml and none of the 51 women developed a 
recurrence during follow up. The follow up was a median of 21 months with a range of 1-
112 months. They concluded that non-radical surgery resulted in low complication rate 
and excellent surgical out comes in well selected patients.  
 
Fanfani et al (2014) looked at the sexual and reproductive outcomes in women with early 
stage cervical cancer after excisional cone biopsy and laparoscopic lymphadenectomy, as 
fertility sparing surgery, in Italy. Twenty three patients with an average age of 30 years 
participated in the study. After the treatment, all the women had regular menstruation 
with 30% reporting increased dysmenorrhea. One (4,4%) experienced cervical stenosis. 
Of the 10 patients that attempted conception, 6 (60%) conceived spontaneously whilst 4 
(40%) underwent in vitro fertilization and embryo transfer with 1 (25%) being successful. 
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Sexual complaints included inadequate lubrication, performance anxiety and dyspareunia, 
which resolved in the subsequent 3 months.  
 
Persistence and recurrence of Cervical disease 
In addition to being a therapeutic and diagnostic procedure, certain aspects related to the 
cone biopsy may predict persistent or recurrent disease. Numerous studies have been 
performed looking at different variables with respect to demographics and cone histology 
as predictors of persistent or recurrent disease. Many of these have shown conflicting 
results. Moore et al in (1995) reviewed 1272 patients of whom 311 had a subsequent 
hysterectomy within one year.  The initial histology was HSIL in 57.3% of cases 
(727/1272) and 3.2% showed invasive cancers (42/1271). Findings were either normal or 
low grade SIL in 40% (53/1272) cases. Residual disease was defined as CIN or cancer in 
the hysterectomy specimen.  The following factors were evaluated for predictive value of 
residual disease : age, race, gravidity, parity, socioeconomic status, cigarette smoking, 
marital status, degree of dysplasia, margin and endocervical gland involvement and status 
of the endocervical curettage. They found that 34% (106/311) of hysterectomy specimens 
had residual disease and by multivariate analysis only increasing age and degree of 
dysplasia were predictive of residual disease. Margin involvement was not predictive in 
this study. The concern with this study is the high degree of persistent disease in the 
hysterectomy specimens which may suggest poor technique. 
A recent study by Shaco-Levy et al (2014) also found older age (p=0.03) to be associated 
with persistent/recurrent disease as well as involvement of the cone margins (focal hazard 
ratio = 17, p,0.001; extensive : hazard ratio =28, p< 0.001). 
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In contrast,  Ramchandi et al (2007), found age not to be a predictor of recurrence or 
residual disease. In their multivariate analysis, the endocervical curettage and the 
endocervical margin status were  significant predictors of recurrent/persistent disease. 
However when the degree of dysplasia and the ectocervical margin status were included 
in the multivariate analysis, endocervical margin status (OR 6.761; 95% CI, 2.7-17.2) and 
severity of cervical disease (OR, 1.930; 95% CI 1.038,3.59) were the only statistically 
significant predictors of persistent/recurrent cervical neoplasia. Postmenopausal status 
was also shown to be a predictor in another study (Saeaib et al 2009). Many studies have 
found severe degree of dysplasia, multiple quadrant involvement and positive margins to 
be predictive of persistence/ recurrence (Saeaib et al 2009;  Tillmanns et al 2006; Moore 
et al 1995; Ramchandani et al 2007; Leguevaque et al 2010; Lubrano et al 2012 & Shaco-
Levy et al 2014). 
 
HIV status is another aspect that has been studied in relation to persistence/recurrence of 
disease.  Massad et al (2007) looked at the outcomes after treatment of cervical 
intraepithelial neoplasia among women with HIV.  Women in two prospective cohort 
studies, the Women’s Interagency HIV Study (WIHS) and the HIV Epidemiology 
Research Study (HERS) were followed up 6 monthly after treatment with CIN using 
HPV testing and cytology with colposcopy as indicated. Identification of CIN or SIL 
(squamous intraepithelial neoplasia) within 6 months was defined as treatment failure and 
later disease as recurrence. Follow up was available for 170 HIV positive and 15 HIV 
negative women. Treatment failed in 45% of women (79 HIV positive and 5 HIV 
negative). 
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Failure was noted to be more likely in women with  
- lower CD4 counts(<200 cell/microL: OR =2.96, 95% CI 1.4-6.20) 
- detectable HPV DNA (OR 8.2; 95% CI 1.8-37.4, p=0.01) 
In the multivariate analysis of HIV positive women, recurrence was more likely among: 
- women treated for CIN 2,3 (HR =2.4; 95%  CI 1.4 - 4.8) 
- those with CD4 counts of less than 200 cells/microL 
- oncogenic HPV infection (HR 2.9 ; 95% CI 1.4-6.1) 
Most failures and recurrences were low grade, with one adenocarcinoma diagnosed. They 
concluded that treatment failure and recurrence was more common in women with HIV 
but is usually low grade (Massad et al 2007) . 
 
Babkina et al (2014) conducted a case control study to investigate the outcomes of 
cervical conization for CIN 2 and 3 in HIV positive women and age- matched HIV 
negative controls and to determine whether positive margins, positive endocervical 
curettage, CD4 count or viral load were associated with the persistence of CIN2,3 or 
residual CIN 2,3 on specimens from repeat excision procedures or hysterectomy. 
Persistent CIN 2/3 was diagnosed in 28 HIV positive women (63%) and 14 HIV negative 
women (31.8%). In HIV positive patients, a positive margin was associated with higher 
persistence after cone biopsy (OR 5.3, 95% CI 1.7-24.14) and 75% had residual CIN 2/3 
on a repeat procedure compared to 45% of controls. In HIV negative patients, positive 
endocervical curettage was associated with a higher persistence rate. However CD4 count 
or viral load was not associated with residual or persistent. Unfortunately, this was a 
small study, with 44 HIV positive patients and 44 age matched controls. 
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Recent studies have also investigated and positively correlated disease persistence and 
recurrence with HR-HPV infection ( Leguevaque et al 2014 & Lubrano et al 2014). 
Unfortunately testing for infection of the cervix for HPV is not offered at GSH at present. 
 
In the context of a low resource setting with a high incidence of cervical cancer, further 
compounded by the HIV epidemic, it is imperative that we offer our patients a good 
quality screening and treatment program. One of these modalities, is the cone biopsy, 
being a diagnostic and sometimes therapeutic procedure but not without morbidity, 
especially for women in the reproductive age group. Cone biopsies, are also being used as 
a treatment option for early stage cancer. 
 
Considering the morbidity associated with cone biopsy, this study aimed to audit the 
indications and outcome of women requiring cone biopsies of the cervix, at Groote 
Schuur Hospital Colposcopy Clinic between 1st April 2010 and 31st October 2013. In 
order to have a better understanding of the spectrum of disease we aimed to review 
patient demographics with respect to age, parity, contraception and HIV status. Where 
patients were HIV positive,  CD4 count and ARV status were documented. Referral 
cytology, indications for cone biopsy, histological outcome and post cone management 
and follow up were reviewed. While studies have been conducted elsewhere (mostly in 
developed countries) regarding the use of cone biopsies, their outcomes, predictors of 
persistent disease and their use in early stage cancer, scanty information regarding the use 
of cone biopsies is available in our local setting.  This study aimed to review current 
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practice and make recommendations for improvement of the service as well as the use of 
cone biopsies for early stage cancer.
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CHAPTER 2 : METHODS 
 
 
The Hygiena database was established in April 2010 at the Colposcopy Clinic, Groote 
Schuur Hospital. All patients attending the colposcopy clinic have their demographic 
details, medical history, clinical complaints and results captured on a structured  
proforma (Appendix A-D), which is entered into the Hygiena Database. Ethics approval 
was attained (HREC REF: 344/2011) on establishment of the database. 
 
A group of women attending colposcopy clinic whose data was entered into our 
anonymised, computerized database and who required a cone biopsy between the 1st 
April 2010 and 31st October 2013 were identified. The data for these women were 
included in the analysis. This allowed for a 10 month follow up of patients until 31st July 
2014. Women who did not receive a cone biopsy or had an incomplete dataset were 
excluded.  
 
Women included in the study were those that required an excisional procedure, in this 
case a cone biopsy, either following a confirmatory biopsy of a high grade lesion or 
immediately after visualization of a high grade precursor at colposcopy.  Women with 
marked disparity between cytology and colposcopy (e.g. HSIL pap but negative 
colposcopy), where the upper limit of the lesion was not seen, where there was evidence 
of a glandular abnormality or evidence of microinvasion, all had cone biopsies performed 
and were included in the study.  Cone biopsy of the cervix involves excision of the 
transformation zone and the endocervical canal as a cone shaped specimen and is 
performed via loop diathermy (hot loop) in the colposcopy clinic or with a surgical 
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scalpel (cold knife) in main theatre. The vast majority of women in the study had cone 
biopsies performed as an outpatient procedure (hot loop cone). 
 
All patients were identified by a study number linked to their hospital folder number to 
ensure confidentiality. 
 
 Data extracted from the database included: 
- date of registration 
- date of birth 
- age 
-  parity 
-  contraception 
- HIV status with CD4 count and ARV status if HIV positive.  
- referral cytology or cytology prior to cone biopsy 
- indication for cone biopsy 
 
HIV status was documented as positive, negative or unknown. While the proforma 
documented CD4 counts as a range i.e. < 200, 200-350 etc. every attempt was made to 
document absolute CD4 counts by confirmation with National Health Laboratory Service 
(NHLS) and folder review. If the absolute CD4 count was unknown a median of the 
range documented was included for analysis.  
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Cytology that precipitated the cone biopsy either at referral or prior to cone biopsy being 
performed at subsequent visits, was included for analysis. Cytology was categorized into 
normal, recurrent LSIL, HSIL, adenocarcinoma in situ (AIS) or microinvasion. 
  There are four main indications for a cone biopsy and these include upper limit of lesion 
not seen (ULNS), disparity between cytology and colposcopy, microinvasion and atypical 
glandular cells (AGUS) on pap smear.  The fifth, being absence of colposcopy, was not 
relevant to our study. Where the indication for the cone biopsy was unclear, review of the 
histology and clinical information provided as well as folder review was conducted to 
confirm the indication. 
 
The histology of all the cone biopsies performed between 1st April 2010 and 31st October 
2013 was reviewed on the NHLS database and categorized as normal, LSIL, HSIL, AIS 
or microinvasive cancer. Cone biopsy margins with respect to the ectocervical and 
endocervical margins were also documented. The denominators may vary in the analysis 
according to the availability of information regarding margins, which was missing in 
some cases. 
 
Folder review as well as review of subsequent histology and cytology was conducted to 
assess post cone biopsy management and compliance with follow up. Visits post cone 
biopsy at 4-6 months, 10-12months and more than 12 months were documented, with 
respect to intervention/treatment and relevant cytology and histology at these visits. 
Patients were categorized as lost to follow up or the end point, i.e. the most invasive 
procedure required for treatment, was documented. . Hence patients were categorized as 
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lost to follow up, follow up only i.e. pap smear/cervical biopsy, simple hysterectomy or 
radical hysterectomy. Patients with invasive cancer requiring radiotherapy, or those 
deemed medically unsuitable for surgery and requiring radiotherapy, were excluded from 
this analysis. 
 
Statistical analysis was performed using Stata version 13.1 (StataCorp LP,4905 Lakeway 
Drive,  College Station, TX 77845, USA).  The distribution of continuous data was 
assessed graphically and using the Shapiro Wilk test.  Normally distributed data were 
summarised using means and standard deviations and analysed using parametric methods 
(independent or paired t-tests as appropriate, or analysis of variance for the comparison of 
3 or more means). Skewed data were summarised using medians and interquartile ranges 
and analysed using non-parametric methods (Mann-Whitney-U-tests or Wilcoxon signed 
rank tests for paired data as appropriate, or the Kruskal Wallis test for the comparison of 
3 or more medians). 
Proportions were compared using Chi-squared tests or Fisher’s exact test as appropriate. 
  
Binomial 95% confidence intervals were used to report the precision of binary variables. 
  
The relationship between binary outcome data and explanatory variables were analysed 







Four hundred and twenty potential cone biopsies were identified on the Hygiena 
database, between 1st April 2010 and the 31st October 2013. Forty four patients were 
excluded due to missing data or the procedure being a LLETZ or punch or wedge biopsy. 
Three hundred and seventy six patients were included in the analysis. 
 
Demographics 
The mean age of the study sample was 42,3 years, with the youngest being 23 and the 
oldest 79 years of age. Parity was known for 375 women, with the majority of women 
30,4% (114/375) having had 2 children, with a range of  0-11.  
 
When considering women in the reproductive age group (i.e. 23-45years for our study), 
just over a third of these women 35,0% (85/243) were not using any form of 
contraception. For those who were, the most common was the long acting injectable used 
by 36,2% (88/243) of women, two of whom were additionally using condoms. Other 
methods were condoms at 16,4% (40/243) and sterilization 10,3% (25/243). A minority 
of women 2,0%(5/243) used the Combined Oral Contraceptive. 
 
The HIV status was negative for 31,9% (120/376) of women, unknown in 11,4% 
(43/376) cases and positive in 56,7% (213/376) of women [95% CI51.6-61.6]. This is 




FIGURE 2.1 : HIV Status of women requiring Cone Biopsy 
 
The CD4 count was known for 205 of the 213 HIV positive females, the median CD4 
being 310, with the range from 5 to 1303. The majority of these women 32,7% (67/205) 
had CD4 counts between 200 and 349. The rest of the categories i.e. 0-199, 350-499 and 
CD4 > 500 all ranged between 22,0% to 22.9% as shown in Table 1 below.  
In addition, 70,9% (151/213) of the HIV positive women were on antiretroviral treatment 
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TABLE 1. Distribution of CD4 counts amongst HIV positive patients 
 
Histology and Cytology of Cone Biopsy 
The indications for cone biopsy were as follows: 30% (112/376) for disparity between 
cytology and colposcopy [95% CI 26,1-43,6], 30,6% (115/376) for suspected 
microinvasive disease [95% CI 26,1-35,4] and 38,6% (145/376) for upper limit of the 
lesion not seen [95% CI 33,7-43,6]. Only 4 patients (1,1%) had suspicion for a glandular 
lesion. This is illustrated in figure 2.2 
 
FIGURE 2.2 Indications for Cone Biopsy 






The final histology of the cone biopsies indicated that the majority of patients i.e. 65,4% 
(246/376) had high-grade cervical cancer precursors (CIN 2,3)[95% CI 9.5-16.2]. Of the 
remainder, 14,4% (54/376) had CIN 1 [ 95% CI 11.2-18.3],  12,5% (47/376) had 
microinvasion [ 95% CI 9.5-16.2], 1,3% (5/376) had AIS [95% CI 0,5-3.2], 5,9% 
(22/376) had no disease [95% CI 3.9-8.7] and in 2 cases the specimen was  suboptimal 
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Both the ecto- and endocervical margins were reported on in 96,6% (363/376) of 
specimens [95% CI 94.1-98.0]. There were cautery artifacts, lost epithelium or no report 
in 9 cases and only the endocervix was reported on in 4 cases.  
 
Where the ectocervix was reported upon, it was clear in only 57,6% (212/368) of cases    
[95% CI 52.5-62.6]. But where involved, this was due to CIN1 in 18,8% (69/368) of 
specimens [95% CI 15.1-23.1] and CIN 2/3 in 18,5% (68/368) of cases [95% CI 14.8-
22.8]. Microinvasive cancer was involved in 3,5% (13/368) of cases, AIS in 1 specimen 
and 4 were suboptimal. 
 
Endocervical margins were only clear in 54,6% (201/368) of specimens. When involved, 
the majority of margins 33,2% (122/368) were involved with CIN2/3. In 6,3% (23/368) 
the endocervix was involved with microinvasive disease, 5,4% (20/368) with CIN 1 and 




FIGURE 2.4 Ectocervical and Endocervical Cone Margin Involvement       
 
Forty seven cases of microinvasion were detected via cone biopsy. Four cancers were 
detected on LLETZ prior to cone biopsy with the subsequent cone biopsies showing CIN 
1 or CIN 2/3.  The vast majority of the cancers i.e. 84,3 % (43/51) were squamous 
carcinoma, with 9,8% (5/51) being adenocarcinoma and 3 equally adenoid basal, adenoid 
cystic and adenosquamous carcinomas. 
Of the 51 cancers detected 26 were stage 1A (56%), of which 21 were 1Ai. Sixteen of the 
51 cancers (33,3%) were stage 1B1 and one was 1B2. Seven patients had stage 2 disease 
















Post cone management and follow up 
 
When reviewing the number of visits post cone biopsy, it is apparent that follow up was 
relatively poor in this study group.  Eleven patients were excluded from the analysis due 
to follow up with radiation oncology and one having demised. Of the 365 remaining 
patients, 17,3% (63/365) never returned, 31,8% (116/365) returned for 1 visit, 23,8% 




FIGURE 2.5 Number of visits Post Cone Biopsy 
 
At the 4-6 month follow-up, data was available for 276 patients. Of these 84,4% 
(233/276) had a Pap smear or cervical biopsy performed. Hysterectomy was performed 
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(two of which were performed after a second cone biopsy). Repeat cone biopsy was 
required for 2,9% (8/276) of women and a LLETZ for 4 women. The results of the 
combined cytology and histology obtained at this visit were as follows:  the majority of 
women 57,6% (159/276) had normal cytology and histology, but 13,4% (37/276) had 
LSIL and 17,4%(48/276) had HSIL.  There were 7 patients with ASC-H and 6 patients 
with ASCUS. In addition there were 19 cancers detected – 18 of these women had cancer 
detected in the original cone biopsy and then underwent hysterectomy by the 4 month 
visit and one patient had a simple hysterectomy for persistent HSIL with cancer detected 
on the hysterectomy specimen. 
 
At the 10-12 month follow up visit, data was available for 182 patients only: 47,7% of 
patients (166/348) either defaulted or there was no data. Of the 182 women seen, 88,5% 
(161/182) had a Pap smear/cervical biopsy or vault smear performed, 4,9% (9/182) 
required a repeat cone biopsy, 3,3% (6/182) a LLETZ, 2,2% (4/182) a simple 
hysterectomy and 0,5% (1/182) a radical hysterectomy. One patient had a colpectomy for 
high grade VAIN (vaginal intraepithelial neoplasia). When combining the results of the 
cytology and histology obtained at this visit, 64,3%(117/182) of women had normal 
cytology and histology, 17,0% (31/182) had HSIL, 13,7% (25/182) LSIL, 4 patients with 
ASCUS, and one with ASC-H. There were 2 cancers and 2 patients with VAIN 1-2.  
 
Data was available for only147 patients at the more than 12 month follow-up visit : 
57,4% (200/348) defaulted or had no data available.  The majority of patients 87,8% 
(129/147) had a Pap smear or cervical biopsy performed, with 3,4% (5/147) requiring a 
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repeat cone biopsy and 4 patients a LLETZ. A further 5,4% (8/147) required a simple 
hysterectomy and 1 patient a vaginectomy.  A review of cytology and histology at this 
visit showed that 70,1% (103/147) patients had normal results, 19,7% (29/147) had HSIL, 
5,4% (8/147) LSIL and there were 4 patients with ASCUS. Three patients had VAIN and 
1 specimen was suboptimal. 
 
Cervical Cancer Management Post Cone Biopsy 
Forty seven cancers were diagnosed or confirmed on cone biopsy during the study period, 
with 4 additional patients having cancer confirmed on a LLETZ followed by a cone 
biopsy showing no residual cancer. Ten patients were referred to radiation oncology and 
one demised shortly after diagnosis. Of the remainder, 11,8% (6/51) were followed up 
with colposcopy, pap smear and cervical biopsy and 56,9% (29/51) had a hysterectomy 
performed, which comprised 9 simple and 20 radical hysterectomies. The majority of 
these hysterectomies i.e. 93,1% (27/29) were performed by the 4 month visit and 2 were 
performed by the 10 month visit. Three patients required a repeat cone biopsy and one a 
LLETZ. One patient defaulted her surgical date and follow up appointments (and 
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Twenty -nine hysterectomies were performed for cancer detected on cone biopsy. The 
histology of these specimens were as follows: 69,0% (20/29) were involved with cancer, 
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Predictors of persistent disease 
Age, parity, HIV status, CD4 count, ARV status and cone biopsy margins were analysed 
as predictors of disease via logistic regression analysis. In the univariate analysis, 
persistent disease was proportionately more commonly diagnosed in women aged 40 – 49 
years compared to younger or older women (Table 2) The relative risk was 1.3 [95% CI 









%Persistent    
disease 
 






<39 166 25.3 1.0 (ref) - 
40-49 123 34.2 1.3 0.9-1.9 0.101 
>50 87 26.4 1.0 0.7-1.6 0.844 
 
TABLE 2. Persistence of disease in different age categories 
 
The mean parity was 2, with women in this category having a 1.2 fold increased risk of 



















1 84 27.4 1.0       (ref) - 
2 114 32.5 1.2 [0.8-1.8] 0.446 
3 81 25.9 0.9 [0.6-1.6] 0.833 
≥	 4 96 28.5 1.0 [0.6-1.6] 0.964 
TABLE 3 Persistence of disease related to parity 
 45 
Persistent disease was found in similar proportions in HIV positive, HIV negative and 



























































TABLE 4 Persistence of disease related to HIV status 
 
 
The majority of women in the study who were HIV positive had CD4 counts between 
250-349 (67/205), however disease was most commonly persistent in those women with 
CD4 between 350-499.There was a 1.2 fold increased risk of persistent disease in the 









































































0.5 – 1.9 
 
0.948 
TABLE 5: Persistence of disease related to CD4 count 
 
HIV status was positive in 213 women in the study. The majority of these women 
(151/213) were on ARV’s. There was a 1.3 fold increased risk of persistent disease in the 
group of women in whom ARV status was unknown. Women on ARV’s had a relative 
























































TABLE 6 : Persistence of Disease related to ARVs 
 
 47 
In the univariate analysis , both endocervical and ectocervical margin involvement, were 
significantly associated with persistent disease if they were involved with CIN 2/3 and 
cancer, but not CIN1 (Table 7). When the endocervical margin was involved with cancer 
or CIN2/3 there was a 2.8 and 1.9 fold increased risk of persistent disease respectively, 







































































TABLE 7 Endocervical Margin and persistence of disease 
 
 
Similiarly, when analyzing the ectocervical margin, those with CIN 2/3 or MI margin 
involvement had a 2.1 and 2.2 fold increased risk of persistent disease respectively. Six 
patients were excluded from this analysis, 1 for AIS and the remainder for cautery artifact 














































































TABLE 8 Ectocervical Margin and persistent disease 
 
The multivariate analysis considered age, parity, HIV status and ecto- and endocervical 
margins as potential predictors of persistent disease. Women aged 40-49years had an 
increased risk of persistent disease (Adjusted RR 1.4 95% CI  1.01-2.0), which was noted 
to be statistically significant in the multivariate analysis (p=0.043). Endocervical margin 
involvement with CIN 2/3 or Cancer and ectocervical margin involvement with CIN2/3 











































123 34.2 1.3[0.9-1.9] 0.101 1.4[1.01-
2.0]  




67 26.4 1.0 
[0.7-1.6] 
0.844 1.0[0.6-1.6]   
Parity 
 
1 84 27.4 1.0 (ref) - 1.0 (ref) - 
 
 
2 114 32.5 1.2[0.8-1.8] 0.446 0.9[0.6-1.2] 0.403 
 
 
3 81 25.9 0.9[0.6-1.6] 0.833 0.7[0.5-1.1] 0.160 
 
 
≥4 96 27.1 1.0[0.6-1.6] 0.964 0.6[0.4-1.1] 0.099 
HIV Status 
 
Negative 120 28.3 1.0 (ref) - 1.0 (ref) - 
 
 
Positive 213 29.1 1.0[0.7-1.5] 0.881 1.1[0.8-1.5] 0.621 
 
 






201 20.4 1.0 (ref) - 1.0 (ref) - 
 
 
CIN 1 20 15.0 0.7[0.3-2.2] 0.575 0.8[0.2-3.2] 0.746 
 CIN 2/3 
 












69 24.6 1.0 (ref) - 1.0(ref) - 
 Clear 
 
212 21.7 0.9[0.5-1.4] 0.608 1.0[0.6-1.6] 0.890 
 CIN 2/3 
 
68 51.5 2.1[1.3-3.4] 0.004 1.8[1.1-3.0] 0.017 
 CA 
 
13	   53.9 2.2[1.1-4.2] 0.019 1.3[0.6-2.7] 0.890 
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CHAPTER 4 : DISCUSSION AND CONCLUSION 
Cervical cancer is the 4th commonest cancer worldwide and the 2nd commonest in South 
Africa. The marked discrepancy in low versus high resource settings is due to either 
nonexistent or poorly implemented cervical cancer screening programmes. Well 
organized screening programmes, as instituted by Nordic countries in the 1960’s have 
been shown to effectively decrease morbidity and mortality associated with cervical 
cancer.  
In South Africa, this has been compounded by the HIV epidemic with HIV positive 
women having a higher prevalence of HPV infection, persistent infection with HPV, 
infection with multiple types of HPV, higher prevalence of cervical cancer precursors and 
presentation at an earlier age with cervical cancer.  
This highlights the need for effective screening and treatment programmes in South 
Africa. Our study analysed 376 women attending Groote Schuur Hospital Colposcopy 
Clinic, between 1st April 2010 and 31st October 2013, who required a cone biopsy with 




The mean age of women requiring cone biopsy in our study was 42.3 yrs. Quantitative 
studies have shown that after two or more negative Pap smears, even screening once 
every 10 years yields a 64% reduction in the incidence of cervical cancer, assuming 
100% compliance (Bulletin of the WHO, 1986).  Well organized screening programs, 
with regular pap smears, have been shown to effectively decrease morbidity and 
 51 
mortality associated with cervical cancer, unfortunately they involve substantial costs to 
provide for the infrastructure, human resources, equipment, and consumables required, 
which are often unaffordable in developing countries. The South African National 
cervical cancer screening programme offers 3 pap smears in a women’s lifetime after the 
age of 30, each 10 years apart. Whilst far from ideal, the mean age of women in our study 
indicates that we are screening the correct age category (Sankaranarayanan, Budukh  & 
Rajkumar  2001).  
  
The majority of women in the study were parous, with a mean parity of 2. In the 
reproductive age group, just over a third of women (35,0%) were not using any form of 
contraception. Of those on contraception, a third (36,2%) were using long acting 
injectables and approximately 10% were sterilized. Only 12,5% of all women in the study 
used condoms and 17,2 % in the reproductive age group, placing most women at risk for 
HIV and HPV. The combined oral contraceptives were rarely used. 
 
 A large proportion of women in the study i.e. just under 60% were HIV positive. 
Numerous studies have previously been mentioned that detail the close association 
between HIV, HPV and cervical cancer supporting the high prevalence of HIV amongst 
the group of women in the study. However, given that the background HIV rate is lower 
i.e. 29% amongst antenatal patients in South Africa, this data must also be viewed in the 
context of HIV positive women more frequently accessing health services and receiving 
pap smears compared  to HIV negative women.  Of note was that the majority of HIV 





 Cytology and histology of Cone biopsy 
The indications for cone biopsy reflected that one third were for disparity between 
cytology and colposcopy, a similar proportion for suspicion for microinvasion and a 
slightly higher percentage 38,6% for ULNS (upper limit of the lesion not seen). Only a 
minority, were for atypical glandular cells. Previous studies have shown ranges from 40-
64% for ULNS, 16-26% for disparity and 1-12% for suspected microinvasion (Massad, 
Chronopoulos & Cejtin 1997; Spitzer et al 1998, El-Toukhy et al 2001).  A study by El- 
Toukhy et al (2001) analysed 100 cold knife cone biopsies between 1987 and 1997, with 
a mean age of 41.8 years and parity 2.  The main indications for cone biopsy were ULNS 
in 64% of patients, disparity in 26% and suspected microinvasion in 12%. CIN was 
histologically proven in 67% of cases, cancer in 7% and AIS in 3%.  We can conclude, 
that while similar proportions of cone biopsies are performed for ULNS at other centers, 
a higher proportion are done for suspicion of microinvasion at GSH. This may reflect a 
higher burden of disease in our setting with 12,5% confirmed cancers on histology. 
 
While histology of the cone biopsy was for high grade disease in most women i.e.65,4% 
(246/376), of note is that  microinvasion was confirmed in 12,5% (47/376) of women and 
as predicted glandular lesions were infrequent. The negative cone rate was almost 6%, 
which is acceptable. 
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There has been conflicting data in the literature regarding the use of loop diathermy 
versus cold knife for cone biopsies, with regard to cautery artifact especially of the 
margins, fragmentation and interpretable results. Ioffe et al (1999) compared 24 cold 
knife cone biopsies with 76 LLETZ and found that all LLETZ had 1+ artifact and in 61% 
of cases it interfered with at least one aspect of evaluation but this was reduced if the 
LLETZ was received in a single specimen. Miroshnichenko et al (2009) found that loop 
electrosurgical excision was associated with an increased number of specimens that 
limited interpretability and an increased number of positive margins.  In comparison 
another study by Huang & Hwang (1999) found smaller mean diameters in the base and 
depth of cone specimens and significantly shorter operating times with loop 
electrosurgical excision procedures compared to cold knife cone biopsies. In addition 
although thermal artifacts of the margin were found in 8.2% of LEEP specimens, there 
was no difficulty on histological interpretation. 
In our study the pathologists were able to comment on margins in the majority (96%) of 
patients, with cautery artifact and lost epithelium in only a few patients. This 
demonstrates that loop electrosurgical excision is a viable option in our setting, where 
most cone biopsies are done on an outpatient basis, especially in light of limited theatre 
time, resources and compliance with follow up. 
 
Unfortunately, there was a high rate of margin involvement, with only just under 60% of 
ectocervical margins and 54,6% of endocervical margins clear of disease. Where 
involved, the pathologists were able to comment on margins in the majority (96%) of 
patients, with cautery artifact and lost epithelium in only a few patients. When the 
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ectocervical margin was involved, this was due to CIN 1 in 18,8% (69/368) of cases, CIN 
2/3 in 18,5%(68/368) of cases and microinvasive disease in 3,5%(13/368) of cases. In 
comparison the endocervical margin was involved with CIN2/3 in 33,2% of specimens, 
microinvasive disease in 6,3%(23/368) and  CIN 1 in 5,4% (20/368) of specimens. This 
highlights the greater degree of disease involving the endocervical margin. A 
retrospective analysis by Mohamed-Noor, Quinn &Tan (1997) in Melbourne, Australia 
reviewed 699 cone biopsies between 1966 and 1992. Abnormal epithelium was 
completely excised in in 82%  (572/699) cases and was incompletely excised in 18% 
(127/699). In those with complete excision, 96,7% were found to have been cured of 
disease at follow up or normal histology of hysterectomy specimens. The overall cure 
rate after incomplete excision was 77%, but was influenced by the site of incomplete 
excision. The cure rate for incomplete excision at the ectocervical margin was 86%, 
incomplete excision at the endocervical margin 68% and at both margins 40% 
demonstrating a risk of recurrence with incomplete excision particularly if the 
endocervical margin was involved.  
Shaco- Levy at al (2014) reviewed 376 women that had cone biopsies performed between 
January 2001 and July 2011. Cone margin involvement was observed in 33% of women, 
with endocervical involvement in 22%, ectocervical in 8%, and both margins in 3% of 
women.  They found that cone margin involvement had a statistically significant 
association with persistent/recurrent disease (focal: hazard ratio =17, p<0.001; extensive: 
hazard ratio=28, p<0.001), particularly when extensively involved. 
Our study demonstrated a high rate of positive cone margin involvement, with 42,4% of 
ectocervical and 45,4% of endocervical involvement, and in particular endocervical  
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involvement with high grade and microinvasive disease. This is concerning when 
compared to international literature, which demonstrated significantly lower percentages 
of margin involvement but showed significant impact on persistent and recurrent cervical 
disease with positive margins. One possible cause for increased margin involvement, is 
larger lesions due to the generally unscreened population group that present to our 
colposcopy clinic. 
 
Forty seven cases of microinvasion were detected directly via cone biopsy (with an 
additional 4 cases of microinvasion detected on previous LLETZ followed by a no 
residual cancer on cone biopsy). The majority of these 84,3% (43/51) were for squamous 
carcinoma which is the commonest histological type of cervical cancer and 9,8%  (5/51) 
were adenocarcinoma. Moodley & Moodley (2009) conducted a retrospective study on 
2930 women from 1995-2002 in the public and private sector in Durban, South Africa. 
They found squamous cell carcinoma to be the commonest type of cervical cancer in the 
public sector occurring in over 80% of patients, correlating with our findings. There was 
a larger percentage of adenocarcinoma in the private sector but this was not statistically 
significant and involved a small number of patients. 
 
Of note, was that 56% (26/51) of cancers were stage 1A and 33% (17/51) were Stage 1B. 
Seven patients had Stage 2 disease and one patient had Stage 4 cancer. Encouragingly 
this reflects the detection of early stage cancer allowing for early treatment and improved 
outcome in screened populations. Hung et al (2014) considered both the survival and 
financial benefits of detection of invasive cervical cancer at earlier stages and estimated 
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the savings in life years and costs from early diagnosis of cervical cancer using an ex post 
approach. Their study reviewed 28 797 patients diagnosed with cervical cancer in the 
period 2002 and 2009 and found that invasive cervical cancer at stages 1-4 had an 
average expected years of life lost of 6.33years, 11.64 years, 12.65 years and 18.61 years 
respectively (Figure 3.1), while the lifetime costs paid by the NHI were $ 7020, $10 133, 
$11 120 and $10 015 US dollars respectively.  The mean lifetime costs for managing 













FIGURE 3.1 : Average expected years of life lost (EYLL) due to cervical cancer 
stratified by stages (The difference (shadowed area) of LE between the cohort of cervical cancer and 
age-, gender-matched reference population, which represents the average EYLL of developing a case of 
cervical cancer) 
(Hung MC,Liu MT, Cheng YM &Wang JD 2014, Estimation of savings of life years and 
cost from early detection of cervical cancer; a follow-up study using nationwide 




 FIGURE 3.2: Survival probability of cervical cancer stratified by stages. 
(Hung MC,Liu MT, Cheng YM &Wang JD 2014, Estimation of savings of life years and 
cost from early detection of cervical cancer; a follow-up study using nationwide 
databases for the period 2002-2009, BMC Cancer, vol 14, no 505) 
 
Post Cone Management and Follow up 
Unfortunately, follow up was relatively poor in this group of women with 17,3% 
(63/365) of women completely lost to follow up.  Of the remainder only 31,8%(116/365) 
returned for 1 visit, 23,8%(87/365) for 2 visits, 28,8%(105/365) for 3 visits and only 5 
patients had four visits. 
Several studies have looked at predictors of cervical screening adherence, which can be 
extrapolated to post cone biopsy follow up. A systematic review by Limmer et al (2014) 
demonstrated several consistent variables associated with screening and follow up. A 
secure financial status, higher level of education, marriage, a high level of acculturation 
and good psychosocial health were positively associated with adherence among US adult 
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women. Similiarly, a recent Denmark study found that women with limited or no use of 
primary health care services, those with primary school education only, unmarried 
women and foreign nationals were poorly compliant (Kristensson et al 2014). Closer to 
home, a study by Batra, Kuhn & Denny (2010)  et al looking at the utilization and 
outcomes of cervical cancer prevention services amongst HIV infected women in Cape 
Town found that only 13% of women were receiving at least one pap smear after HIV 
diagnosis. Most women referred for colposcopy tended to be HIV positive, more than 30 
years of age and had high grade dysplasia (70%). HIV positive women treated with 
excision were significantly more likely than their HIV negative counterparts to undergo 
incomplete excision, experience persistent disease after treatment and  lost to follow up. 
In contrast, a study involving a cohort of HIV positive US women found that better 
colposcopy compliance was associated with less education (OR 2.24, 95% CI 1.12-4.51), 
previous abnormal pap result, study site and higher stress. In this study 68% (222/378) of 
women were compliant with colposcopy referral (Massad et al 2012).  
Interestingly, a study by Greenspan et al (2007) found that the type of excisional 
procedure was significant in predicting compliance. With 74.1% of cold knife cone 
biopsies compliant with follow up compared to 43.2% of LEEP patients. (adjusted RR 
1.64 95% CI 1.3-1.87). Older patients were noted to be more compliant, in the univariate 
but not the multivariate analysis. Severity of disease, race and gravidity were not 
significant predictors. They concluded that given that LEEP is a less invasive in-office 
procedure, it may convey to patients that their condition is less severe. 
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At the 4-6 month follow up data was available for 276 patients with the majority 84,4% 
(233/276) requiring follow up with Pap smear or cervical biopsy. Of the 31 
hysterectomies (19 radical and 12 simple hysterectomies) performed by this visit 27 were 
for cancer detected on cone biopsy and 4 were simple hysterectomies for persistent HSIL, 
one of which showed cancer. Repeat cone biopsy was required for 2,9%(8/275) of 
women and LLETZ for 4 patients. The combined cytology and histology at this visit 
showed that the majority of women 57,6% (159/276) were normal, 13,4%(37/276) had 
LSIL and 18,3%(48/276) had HSIL. Of the 31 hysterectomies performed, 7 were normal, 
5 showed CIN 2/3, and 19 showed cancer. Thus, a significant proportion of women i.e.  
24,3% (67/276) demonstrated persistent/residual disease post cone biopsy at this visit. 
 
At the 10-12month follow up, data was unfortunately unavailable for 47,7% (166/348) of 
patients. The majority of women at this visit 88,5% (161/182) required follow up with 
Pap smear or cervical biopsy, 8,2%(15/182) patients required a repeat excisional 
procedure, 5 required a simple hysterectomy and 1 a radical hysterectomy. While 64,3% 
of women had normal cytology and histology, 19,2% (35/182) demonstrated 
persistent/recurrent disease with HSIL, cancer or VAIN present on cytology or histology. 
 
Data was only available for 148 patients at the more than 12 month follow up with 87,8% 
requiring follow up via Pap smear or cervical biopsy , 6,08% (10/147) requiring a repeat 
excisional procedure, 9 patients a simple hysterectomy and 1 patient a vaginectomy. 
Again 20,4% (30/147) had persistent/recurrent disease with HSIL or VAIN on cytology 
or histology. (Compliance at this visit must be reviewed with caution as patients with a 
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normal 10-12month follow up visit seen after July 2013 would have a more than 12 
month visit scheduled after the study period which may alter data). 
 
A considerable loss to follow up was noted in our study, as highlighted above.  Loss to 
follow up is a feature of colposcopy clinics globally, impacted upon by both patient and 
institutional factors, many of which have been discussed earlier. An important factor, is 
that follow up requires women without symptoms  and a lack/poor understanding  of the 
intention of screening to attend regular clinic visits, which sadly results in failure to do 
so. These are considered random events, with little effect on data interpretation and not 
resulting in systematic error. 
 
Cervical Cancer Management Post Cone Biopsy 
Fifty one cancers were detected during the study period with ten patients referred to 
radiation oncology and one patient having demised shortly after diagnosis. Just under 
60% (29/51) of women had a hysterectomy performed, 20 radical and 9 simple 
hysterectomies. Almost 70% (20/29) of the hysterectomies performed showed residual 
cancer and 13,0%(4/49) demonstrated CIN 2/3. Only 17,3%(5/29) were normal. Sixteen 
of the nineteen radical hysterectomies and 2 of the 8 simple hysterectomies were 
involved with residual cancer.  
Of the remainder of patients with cancer, 3 had repeat cone biopsies, 1 patient had a 
LLETZ and 11.8% (6/51) were followed up with colposcopy, pap smear and/or cervical 
biopsy (one of these patients was medically unfit for further oncological intervention). 
None of these patients demonstrated any residual cancer, however 5 of them had HSIL on 
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subsequent histology and cytology. These patients were aged between 25-39years, with 
one patient aged 47yrs and the majority (7/9) were stage 1Ai. The other two were stage 
1Aii and 1Bi.  
Cone biopsy with adequate margins and pelvic lymphadenectomy is now being 
considered as a treatment option for early stage cancer in young women requiring fertility 
sparing surgery. Lee et al (2014) performed a retrospective analysis of 169 patients who 
had Stage 1Ai cervical cancer after cone biopsy, between 1997 and 2007 in Seoul. During 
the study period, 18 patients had a cone biopsy as definitive treatment and 151 patients 
subsequently underwent simple or radical hysterectomy with lymphadenectomy. No 
parametrial involvement or lymph node metastasis was noted in any of the patients. Of 
the 62 patients who had negative resections, only one presented with residual tumour in 
subsequent surgery and only one recurrence of disease was identified in the total sample 
of 169 women with a median follow up time of 99 months.  
The study data suggests that in our setting cone biopsy may be an appropriate treatment 
option for well selected young patients with early stage cervical cancer preferably stage 
1Ai. However, given the persistence of high grade disease noted on follow up these 
patients require extensive counseling regarding the risk of recurrence and need for close 







Predictors of Persistent disease 
 
Vast arrays of studies have looked at predictors of persistent/residual disease post cone 
biopsy with conflicting results. Significant predictors that have been implicated in 
persistence have been increasing age(> 35years), parity and severe dysplasia. High risk 
HPV, positive cone margins and positive endocervical curettage have been shown to be 
statistically significant as predictors of residual/ recurrent disease. In our setting HR-HPV 
is unavailable and endocervical curettage is not used as part of standard protocol.  
 
Age, parity, HIV status including CD4 and ARV status as well as cone biopsy margin 
involvement were included in the univariate analysis and age, parity and HIV status were 
analysed in the multivariate analysis. Persistence was defined as a LLETZ, Cone biopsy, 
hysterectomy or colpectomy required on follow up or CIN 2/3, Cancer or VAIN present 
on histology or cytology at follow up. 
 
In the univariate analysis women aged 40-49 years had a slightly increased risk of 
persistent disease (34.2%) than younger or older women with a Relative Risk of 1.3 [ 
95% CI 0.9-1.9; p value 0.101], but this was not statistically significant.  
In addition, both ectocervical and endocervical margin involvement with CIN 2/3 and MI 
were associated with an increased risk of persistent disease. Where the endocervical 
margin was involved with CIN there was 38.5% persistent disease (RR1.9 95% CI 1.3-
2.70) which was statistically significant p=0.000. There was a increased risk when the 
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endocervical margin was involved with microinvasive disease with 56.5% persistence 
(RR 2.8 95% CI 1.8-4.3). 
When the ectocervical margin was involved with CIN 2/3, there was 51.4% persistence 
of disease (RR 2.1 95% CI 1.3-3.4: p value= 0.002). Involvement with microinvasion 
increased this persistence marginally to 53.9% (RR 2.2 95% CI 1.1-4; p value = 0.019). 
 
Interestingly, whilst 56,7% (213/276) of women in the study were HIV positive, their 
positive status was not associated with an increased risk of persistent disease in the 
univariate analysis[ RR 1.0 95% CI O.7-1.5]. HIV positive and negative women reflected 
the same risk of persistent disease, and there was a slightly decreased risk in those with 
unknown status (RR 0.9 95% CI 0,5-1,6]. Most HIV positive women had CD4 counts 
between 200 and 349, but only those with CD4 counts between 350-499 had a slightly 
increased risk of persistent disease, that was not statistically significant (RR 1.2 95%CI 
0.5-1.9).Whilst one might intuitively expect HIV positive women, who present more 
frequently for colposcopy and demonstrate high grade lesions, to  have greater 
persistence of disease this may be explained by the fact that 70% of HIV positive women 
in the study were on ARV’s. In the univariate analysis, women on ARVS had a slightly 
decreased risk of persistence (RR 0.9 95%CI 0.65-1.5) and those whose ARV status was 
unknown a marginally increased risk (RR 1.3 95%CI 0.4-4.1). Ahdieh-Grant et al (2004) 
assessed the association between the use of Highly Active Antiretroviral Therapy 
(HAART/ARVS) and regression of squamous intraepithelial neoplasia in HIV infected 
women enrolled in the Women’s Interagency HIV study, a large multicenter, prospective 
cohort study. Of the 2059 HIV infected participants, 312 HIV infected women had 
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normal cervical cytology at baseline and were subsequently diagnosed during 7years of 
follow-up with incident squamous intraepithelial neoplasia. Pap smears, CD4+ T cell 
counts and information regarding use of HAART was obtained every 6 months. Of the 
312 women, 141 had lesions that regressed to normal cytology with a median time to 
regression of 2.7years. Overall, the incidence of regression increased over time after 
HAART was introduced. Before HAART was introduced, the rate of regression was 
0,0% (95% CI 0,0%-2,4%). After HAART was introduced, the rate was 12,5% (95% CI 
9.9% to 15.1%) and was related to post HAART CD4+T cell counts (p value=0.002). 
They noted that HAART was associated with an increased regression of SIL among HIV 
infected women, and among women who used HAART. However, the majority of 
cervical lesions among HIV infected women, even among individuals who used HAART, 
did not regress to normal.  
Of note, is that we did not have access to viral loads in our study, which more recent 
literature has shown to be a more important predictor of outcome than CD4 counts. 
 
In the multivariate analysis, age, parity, HIV status and margin involvement were 
analysed as predictors of persistent disease.  Parity and HIV status were not associated 
with an increased risk of persistent disease. Women aged 40-49 years demonstrated an 
increased risk of persistent disease, which was statistically significant (Adjusted RR 1.4 
:95% CI 1.01-2.0; p value =0.043). Endocervical margin involvement with CIN 2/3 
(Adjusted RR1.5 95% CI 1.04-2.3: p value =0,031) and microinvasion (adjusted RR 2.4 
95%CI 1.4-4.3) were significantly associated with an increased risk of persistent disease. 
This was statistically significant. 
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In the univariate analysis ectocervical involvement with CIN 2/3 and cancer were 
significantly associated with persistent disease, however in the multivariate analysis only 
ectocervical margin involvement with CIN 2/3 was associated with an increased risk of 





In this study we conducted an audit of the cone biopsies performed at Groote Schuur 
Colposcopy clinic between 1st April 2010 and 31st October 2013 with respect to 
demographics, indications for cone biopsy, histology of the cone biopsy, post cone 
management, compliance and follow up. 
 
Three hundred and seventy six cone biopsies were conducted during the study period, 
with a mean age of  42.3 years and mean parity of 2, supporting current South African 
National Screening Guidelines and reiterating that we are screening the correct age 
category of patients. Of concern was that almost 50% of women in this group were not 
using any form of contraception and only 11% were using condoms, placing them at risk 
of unwanted pregnancy, HIV and HPV. Almost 60% (213/376) of women in the study 
were HIV positive, with the majority having CD4 counts between 200 -349 and 70% of 
HIV positive women on ARV’s. While this supports the association between HIV and 
high grade cervical dysplasia it may also demonstrate that HIV positive women have 
more access to healthcare, Pap smears and colposcopy referral than HIV negative 
women. 
 
The indications for cone biopsies were appropriate, evidenced by the fact that high grade 
dysplasia was confirmed on almost two thirds of specimens and microinvasion on 12,5% 
(47/376) with a negative cone rate of 5,9%.  Unfortunately, there was a significant 
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proportion of positive margin involvement particularly of the endocervical margin, 
contributing to persistent disease. 
 
Fifty one cancers were detected during the study period, with 84% of these being early 
stage disease detection thus improving the survival and outcome for these patients as well 
as the financial burden associated with advanced stage disease. Twenty-nine 
hysterectomies were performed for cancer in the study with 9 patients followed up with 
repeat excisional procedure or with colposcopy, Pap smear or cervical biopsy. These 
were young patients with early stage disease that did not demonstrate any residual cancer 
but did have high-grade disease on follow up. The study data suggests cone biopsy may 
be an appropriate treatment option for well selected young patients with early stage 
cervical cancer preferably stage 1Ai in the reproductive age group. However counseling 
regarding the risk of recurrence/persistence and the need for close monitoring, and 
compliance with follow up is required. Given that this was a very small group of women, 
further studies are required to determine if this a feasible option in our setting.  
 
Unfortunately, follow up was poor in this group of women and is an area that needs 
attention to decrease the burden of disease as well as disease progression. Counseling and 
education, improved psychosocial health, easier/local access to treatment sites, financial 
assistance as well as patient tracing and call back are some of the areas that must be 
reviewed to improve patient compliance and follow up. 
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Age, parity, HIV status, CD4 count, ARV status and cone margin involvement were 
analysed as predictors of persistence disease. In the multivariate analysis, age 40-49years, 
ectocervical margin involvement(with CIN 2/3) and endocervical margin involvement 
were all associated with an increased risk of  persistent disease that was statistically 
significant. This subgroup of patients, should be closely monitored for persistent disease. 
Parity, HIV status and CD4 count were not associated with persistent disease. However 
HIV positive patients on ARVs demonstrated a slightly decreased risk of persistent 
disease in the univariate analysis, which may reflect disease regression for patients on 
ARVs. This is an area that needs further investigation and study. 
 
In conclusion, the use of cone biopsy is a valid diagnostic and sometimes therapeutic 
procedure at Groote Schuur Hospital with significant detection of high grade disease and 
cervical cancer. Women aged 40-49years and positive cone margins are strong predictors 
of persistent disease. Improved compliance and a reduction in positive margins are two 
areas that need to be addressed to improve the current treatment programme. Use of cone 
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